Provided by Tiger Trade Technology Pte. Ltd.

Tiziana Life Sciences PLC

0.9056
-0.0644-6.64%
Post-market: 0.9050-0.0006-0.07%19:40 EDT
Volume:414.83K
Turnover:386.17K
Market Cap:115.01M
PE:-5.81
High:0.9800
Open:0.9700
Low:0.9056
Close:0.9700
52wk High:2.35
52wk Low:0.7615
Shares:127.00M
Float Shares:64.88M
Volume Ratio:0.50
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1558
EPS(LYR):-0.1558
ROE:-924.32%
ROA:-115.96%
PB:2211.75
PE(LYR):-5.81

Loading ...

Tiziana Life Sciences - Topline Data from Inform-ms Trial Expected Late Q3 or Early Q4 2026

THOMSON REUTERS
·
Jun 25

Tiziana Life Sciences Executive Chairman Gabriele Cerrone Increases Holdings

MT Newswires Live
·
Jun 15

Tiziana Life Sciences’ COO and CFO Keeren Shah files initial beneficial ownership statement

Reuters
·
May 23

Tiziana Life Sciences Completes Patient Enrollment for Phase 2a Multiple Sclerosis Trial

MT Newswires Live
·
May 21

Tiziana fully enrolls Phase 2 placebo-controlled MS trial

TIPRANKS
·
May 21

Tiziana completes enrollment in Phase 2a intranasal foralumab trial in secondary progressive MS

Reuters
·
May 21

Tiziana Fully Enrolls Its Phase 2 Placebo Controlled Multiple Sclerosis Trial

THOMSON REUTERS
·
May 21

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

MT Newswires Live
·
May 20

Tiziana Life Sciences announces updated intranasal foralumab data

TIPRANKS
·
May 19

Tiziana Life Sciences Says Multiple Sclerosis Therapy Shows Tolerability, Fatigue Improvement in Updated Clinical Data

MT Newswires Live
·
May 19

Tiziana reports positive expanded-access data for intranasal foralumab in non-active SPMS

Reuters
·
May 19

Tiziana Life Sciences Ltd - Foralumab Well Tolerated With No New Safety Signals Identified

THOMSON REUTERS
·
May 19

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

THOMSON REUTERS
·
May 19

Tiziana Life Sciences Ltd - Intranasal Foralumab Well Tolerated Over Extended Treatment as of March 2026

THOMSON REUTERS
·
May 19

Tiziana Phase 2 trial for foralumab shows reduced brain inflammation

TIPRANKS
·
May 14

Tiziana FY25 net loss widens to USD 18.4 million; R&D expense rises to USD 10.28 million

Reuters
·
May 02

Tiziana Life Sciences delays filing annual Form 20-F for 2025 fiscal year

Reuters
·
May 01

Tiziana Life announces publication of preclinical data in bioRxiv preprint

TIPRANKS
·
Apr 16

Tiziana reports preclinical data showing intranasal foralumab eases Long COVID brain inflammation in mice

Reuters
·
Apr 16

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-Cd3 Antibody Attenuates Long Covid Neuroinflammation and Improves Cognitive Function

THOMSON REUTERS
·
Apr 16